Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-401-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.73 million
Profitability
Miscellaneous
Employees112
OptionableOptionable
Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine Inc (NASDAQ:EDIT) announced its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.40. The company earned $14.52 million during the quarter, compared to analyst estimates of $9.83 million. Editas Medicine had a negative return on equity of 53.15% and a negative net margin of 410.68%. The firm's revenue was up 131.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.64) earnings per share. View Editas Medicine's Earnings History.
When is Editas Medicine's next earnings date?
What price target have analysts set for EDIT?
9 analysts have issued 12-month target prices for Editas Medicine's shares. Their predictions range from $36.00 to $67.00. On average, they expect Editas Medicine's stock price to reach $47.4286 in the next year. This suggests a possible upside of 81.0% from the stock's current price. View Analyst Price Targets for Editas Medicine.
What is the consensus analysts' recommendation for Editas Medicine?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Editas Medicine.
Has Editas Medicine been receiving favorable news coverage?
News coverage about EDIT stock has trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Editas Medicine earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term.
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Regenxbio (RGNX), Autolus Therapeutics (AUTL) and Rubius Therapeutics (RUBY).
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the folowing people:
- Ms. Katrine S. Bosley, CEO, Pres & Director (Age 50)
- Dr. Andrew A. F. Hack, Chief Financial Officer (Age 44)
- Dr. Charles Albright, Chief Scientific Officer (Age 60)
- Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
- Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 64)
When did Editas Medicine IPO?
(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Who are Editas Medicine's major shareholders?
Editas Medicine's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.15%), Virtu Financial LLC (0.02%) and Edge Wealth Management LLC (0.01%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.
Which institutional investors are selling Editas Medicine stock?
EDIT stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Nisa Investment Advisors LLC. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright, Katrine Bosley and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.
Which institutional investors are buying Editas Medicine stock?
EDIT stock was purchased by a variety of institutional investors in the last quarter, including Edge Wealth Management LLC. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.
How do I buy shares of Editas Medicine?
Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Editas Medicine's stock price today?
One share of EDIT stock can currently be purchased for approximately $26.21.
How big of a company is Editas Medicine?
Editas Medicine has a market capitalization of $1.26 billion and generates $13.73 million in revenue each year. The company earns $-120,320,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Editas Medicine employs 112 workers across the globe.
What is Editas Medicine's official website?
How can I contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]
MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
